PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Byannli authorised in Britain for schizophrenia treatment

Market authorisation for twice-yearly schizophrenia treatment which offers patients much-needed medication continuity

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in Britain for the long-acting atypical antipsychotic therapy Byannli–the six-monthly paliperidone palmitate (PP6M)–for the maintenance treatment of schizophrenia in adult patients.

This makes PP6M the first twice-yearly treatment for adults living with schizophrenia to be approved by the MHRA, with the longest available dosing interval for antipsychotic medication in Britain.

PP6M is a long-acting injectable (LAI) that works by dissolving and entering the bloodstream slowly, resulting in continuous absorption of paliperidone palmitate over a six-month period.

The MHRA authorisation is based on data from the Route 6 Study; a randomised, double-blind phase 3 global study designed to demonstrate that PP6M is not less effective than PP3M for the prevention of relapse in participants who were previously stabilised on a shorter-acting formulation of paliperidone palmitate.

Schizophrenia affects approximately 20 million people worldwide and nearly 300,000 people in the UK. According to the NHS website, symptoms include hallucinations, delusions–unusual beliefs not based on reality–and not caring about one’s personal hygiene.

Antipsychotic medication is an essential component in the treatment of schizophrenia and helps to prevent symptoms and relapse. As nearly 70% of people with schizophrenia do not receive the appropriate care, this highlights the importance of early intervention, in order to improve patient outcomes.

Professor David Taylor, Director of Pharmacy and Pathology at the Maudsley Hospital, commented: “Schizophrenia is a chronic and severe brain disorder and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication.”

He added: “Long-acting injectable treatments can offer better protection against relapse and greater patient convenience compared with oral medication. This authorisation is a major step forward for people living with schizophrenia, providing them with the option of a treatment that needs to be administered only twice a year.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026